News

ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea

PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea…

8 months ago

Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024

BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and…

8 months ago

Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones

Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever…

8 months ago

Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio

Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations;…

8 months ago

OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference

MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in…

8 months ago

Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2023 and Provides Initial 2024 Guidance

MINNEAPOLIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on…

8 months ago

Health Canada Accepts for Review Medexus’s New Drug Submission for Topical Terbinafine

Topical terbinafine has been widely used in other markets to treat fungal nail infectionsIf and when approved, the product will…

8 months ago

Occlutech(R) Announces FDA Approval of its Occlutech(R) ASD Occluder and Occlutech(R) Pistol Pusher, a Minimally Invasive Cardiac Device and Delivery System to Treat Atrial Septal Defects

SCHAFFHAUSEN, CH / ACCESSWIRE / January 8, 2024 / Occlutech Holding AG Occlutech ASD Occluder delivers positive procedural outcomes with…

8 months ago

Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Process Qualification Run Completed

LONDON, UK / ACCESSWIRE / January 8, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), which is developing new therapies and treatments…

8 months ago

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2024

– Revenue of $1,013.1 Million Exceeds Guidance – – 5.2% Organic Constant Currency Revenue Growth ex. COVID-19, also Exceeding Guidance…

8 months ago